Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zydus LifesciencesBOM:532321 +1.38%94 Days Inventory is 131.85 as of Jun. 2026, which is 33% below its 10-year median of 196.29. GuruFocus rates BOM:532321 with a GF Score™ of 94/100 and a GF Value™ of ₹1,218.89 (Fairly Valued). The stock has 3 warning signs investors should review. Among 921 Drug Manufacturers companies, Zydus Lifesciences ranks worse than 71.55% on this metric.
The historical rank and industry rank for Zydus Lifesciences's Days Inventory or its related term are showing as below:
BOM:532321'
s Days Inventory Range Over the Past 10 Years
Min: 158.78 Med: 196.29 Max: 228.08
Current: 225.05
During the past 13 years, Zydus Lifesciences's highest Days Inventory was 228.08. The lowest was 158.78. And the median was 196.29.
BOM:532321's Days Inventory is ranked worse than 71.55% of 921
companies
in the Drug Manufacturers industry
Industry Median: 165.34
vs BOM:532321: 225.05
Zydus Lifesciences's Days Inventory
increased
from Jun. 2025 (123.20) to Jun. 2026 (131.85).
It might indicate that Zydus Lifesciences's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Zydus Lifesciences's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.69.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Zydus Lifesciences's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.75.
Zydus Lifesciences (BOM:532321) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Zydus Lifesciences's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Zydus Lifesciences's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Zydus Lifesciences Days Inventory Related Terms
Zydus Lifesciences Days Inventory Historical Data
* Premium members only.
The historical data trend for Zydus Lifesciences's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zydus Lifesciences Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Days Inventory distribution charts can be found below:
* The bar in red indicates where Zydus Lifesciences's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zydus Lifesciences (BOM:532321) has a Days Inventory of 131.85 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Zydus Lifesciences and its competitors. This is 33% below median its historical median of 196.29. Over the past decade, Zydus Lifesciences' Days Inventory has ranged from 158.78 to 228.08. According to the industry distribution chart, Zydus Lifesciences ranks #659 out of 921 companies in the Drug Manufacturers industry, placing it in the top 71.6%.
Is Zydus Lifesciences' Days Inventory too high?
Zydus Lifesciences' current Days Inventory of 131.85 is 33% below median its 10-year median of 196.29. Over the past 10 years, this metric has ranged from a low of 158.78 to a high of 228.08. The Drug Manufacturers industry median Days Inventory is 165.34. Zydus Lifesciences' value of 131.85 is 20.3% below this industry median. Based on the distribution chart, Zydus Lifesciences ranks #659 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zydus Lifesciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zydus Lifesciences' Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zydus Lifesciences ranks #659 out of 921 companies for Days Inventory. This places Zydus Lifesciences in the lower half of its industry. The industry median Days Inventory is 165.34. Zydus Lifesciences' value of 131.85 is 20.3% below this benchmark. Historically, Zydus Lifesciences' own Days Inventory has ranged from 158.78 to 228.08 over the past decade. While the company's 10-year median is 196.29 vs. the industry median of 165.34, Zydus Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 165.34, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zydus Lifesciences's current Days Inventory of 131.85 is 20.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Zydus Lifesciences and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 165.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zydus Lifesciences's current Days Inventory is 131.85, which is 33% below median its own 10-year median of 196.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zydus Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Zydus Lifesciences (BOM:532321) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,218.89, compared to a current price of ₹1,153.00 — trading 5.4% below its estimated fair value. The current Days Inventory is 131.85, which is 33% below median its 10-year median of 196.29 and 20.3% below the Drug Manufacturers industry median of 165.34. Zydus Lifesciences' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Zydus Lifesciences (BOM:532321), the current Days Inventory is 131.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zydus Lifesciences (BOM:532321) Overvalued in 2026?
Based on GuruFocus' analysis, Zydus Lifesciences stock appears to be undervalued.
The current stock price of ₹1,153.00 is trading 5.4% below its estimated GF Value™ of ₹1,218.89.
GuruFocus considers Zydus Lifesciences to be Fairly Valued.
Key valuation signals for BOM:532321:
Days Inventory: 131.85 (33% below median its 10-year median of 196.29)
GF Value™: ₹1,218.89 vs. price of ₹1,153.00 (5.4% below fair value)
Industry Position: 20.3% below the Drug Manufacturers median (#659 of 921)
No single metric tells the full story. See the BOM:532321 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
94GF Score
Get the complete analysis for BOM:532321
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532321 has been successfully added to your 
